Kindeva Opens New UK HQ and Manufacturing Site 

Kindeva, a global CDMO and drug delivery provider, has opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park, in Loughborough. The facility significantly expands Kindeva’s MDI services and will develop and test next-generation propellants (NGP) as the industry prepares to move to more environmentally friendly products. 

The 150,000 sq. ft. site offers a range of services across drug development, from early-stage viability, analytical method development, to commercial analysis. It has a Chemistry, Manufacturing and Controls (CMC) strategy and regulatory department to help customers through complex compliance hurdles at every stage of the drug development journey.

Commenting on the new site, Milton Boyer said, “The opening of our Loughborough Headquarters marks a significant milestone in Kindeva’s growth strategy as we continue to innovate, scale, and expand our global footprint.”

The Loughborough HQ will be responsible for developing and analysing NGPs as the industry faces significant legislation aimed at reducing the environmental impact of the propellants currently used in pressurized metered-dose inhalers (pMDIs).